Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

[1]  M. Brownstein,et al.  Origin of glutamate-decarboxylase (GAD)-containing cells in discrete hypothalamic nuclei , 1977, Brain Research.

[2]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[3]  D. Clair,et al.  Association within a family of a balanced autosomal translocation with major mental illness , 1990, The Lancet.

[4]  D. Housman,et al.  Follow-up report of potential linkage for schizophrenia on chromosome 22q: Part 3. , 1995, American journal of medical genetics.

[5]  R. Steinpreis.  The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis , 1996, Behavioural Brain Research.

[6]  M. Karayiorgou,et al.  Dissecting the genetic complexity of schizophrenia , 1997, Molecular Psychiatry.

[7]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[8]  M. Karayiorgou,et al.  The gene encoding proline dehydrogenase modulates sensorimotor gating in mice , 1999, Nature Genetics.

[9]  R. Nicoll,et al.  PSD-95 involvement in maturation of excitatory synapses. , 2000, Science.

[10]  P. Goldman-Rakic,et al.  Destruction and Creation of Spatial Tuning by Disinhibition: GABAA Blockade of Prefrontal Cortical Neurons Engaged by Working Memory , 2000, The Journal of Neuroscience.

[11]  S. Maxwell,et al.  Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Cools,et al.  Animal models for the negative symptoms of schizophrenia , 2000, Behavioural pharmacology.

[13]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[14]  P. Gean,et al.  A Role for the PI-3 Kinase Signaling Pathway in Fear Conditioning and Synaptic Plasticity in the Amygdala , 2001, Neuron.

[15]  D. Valle,et al.  Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. , 2001, Cancer research.

[16]  J. Beckmann,et al.  A highly significant association between a COMT haplotype and schizophrenia. , 2002, American journal of human genetics.

[17]  Ellen M Wijsman,et al.  Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Abecasis,et al.  Genetic variation in the 22q11 locus and susceptibility to schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Linyi Chen,et al.  The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase , 2002, The Journal of cell biology.

[20]  D. Bredt,et al.  Protein palmitoylation: a regulator of neuronal development and function , 2002, Nature Reviews Neuroscience.

[21]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[22]  A. Sampson,et al.  Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia , 2003, The Journal of Neuroscience.

[23]  Lorenzo D Botto,et al.  A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. , 2003, Pediatrics.

[24]  Christopher P Austin,et al.  DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. , 2003, Human molecular genetics.

[25]  Michael C O'Donovan,et al.  A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. , 2003, American journal of human genetics.

[26]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[27]  P. Conn,et al.  Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  Maria Karayiorgou,et al.  Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia , 2004, Nature Genetics.

[29]  L. Mittelman,et al.  A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication* , 2004, Journal of Biological Chemistry.

[30]  D. Cyril D’Souza,et al.  Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects , 2005, Psychopharmacology.

[31]  R. Murray,et al.  Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[32]  Bita Moghaddam,et al.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia , 2004, Psychopharmacology.

[33]  Pavla Stopkova,et al.  Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia , 2004, Biological Psychiatry.

[34]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[35]  Hillel Adesnik,et al.  Identification of PSD-95 Palmitoylating Enzymes , 2004, Neuron.

[36]  M. Karayiorgou,et al.  The molecular genetics of the 22q11-associated schizophrenia. , 2004, Brain research. Molecular brain research.

[37]  J. Rain,et al.  Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders , 2004, Molecular and Cellular Neuroscience.

[38]  Bruce H. Morimoto,et al.  NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). , 2006, CNS drug reviews.

[39]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[40]  S. Duan,et al.  A family-based association study of schizophrenia with polymorphisms at three candidate genes , 2005, Neuroscience Letters.

[41]  Christopher A. Ross,et al.  A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development , 2005, Nature Cell Biology.

[42]  Jie Qin,et al.  Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice , 2005, Nature Neuroscience.

[43]  C. Lindsley,et al.  A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[44]  M. Cannon,et al.  The role of obstetric events in schizophrenia. , 2005, Schizophrenia bulletin.

[45]  Paul J. Harrison,et al.  Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology , 2006, Biological Psychiatry.

[46]  Barbara F. Akum,et al.  Activity-Independent Regulation of Dendrite Patterning by Postsynaptic Density Protein PSD-95 , 2006, The Journal of Neuroscience.

[47]  Heather C Whalley,et al.  A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms , 2006, Nature Neuroscience.

[48]  P. Conn,et al.  Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[49]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[50]  D. Talmage,et al.  Cholinergic circuits and signaling in the pathophysiology of schizophrenia. , 2007, International review of neurobiology.

[51]  R. Freedman.  Exacerbation of schizophrenia by varenicline. , 2007, The American journal of psychiatry.

[52]  K Mizuguchi,et al.  Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia , 2007, Molecular Psychiatry.

[53]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[54]  R. Gainetdinov,et al.  The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.

[55]  J. Lasalde-Dominicci,et al.  Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking , 2007, Cellular and Molecular Neurobiology.

[56]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[57]  Sheng Li,et al.  Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. , 2007, The Journal of clinical psychiatry.

[58]  F. Bymaster,et al.  Towards a muscarinic hypothesis of schizophrenia , 2007, Molecular Psychiatry.

[59]  C. Plata-salamán,et al.  Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures , 2007, Journal of Molecular Neuroscience.

[60]  B. Hemmings,et al.  Physiological roles of PKB/Akt isoforms in development and disease. , 2007, Biochemical Society transactions.

[61]  D. Talmage,et al.  Presynaptic Type III Neuregulin1-ErbB signaling targets α7 nicotinic acetylcholine receptors to axons , 2008, The Journal of cell biology.

[62]  Sarah E. Forster,et al.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. , 2008, The American journal of psychiatry.

[63]  Joseph A. Gogos,et al.  Strong association of de novo copy number mutations with sporadic schizophrenia , 2008, Nature Genetics.

[64]  R. Gainetdinov,et al.  Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.

[65]  L. Hong,et al.  Evidence of Missense Mutations on the Neuregulin 1 Gene Affecting Function of Prepulse Inhibition , 2008, Biological Psychiatry.

[66]  Vladimir I. Vladimirov,et al.  AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families , 2008, Biological Psychiatry.

[67]  L. Mei,et al.  Neuregulin 1 in neural development, synaptic plasticity and schizophrenia , 2008, Nature Reviews Neuroscience.

[68]  Peter Stoeter,et al.  Association of 5′ end neuregulin-1 (NRG1) gene variation with subcortical medial frontal microstructure in humans , 2008, NeuroImage.

[69]  M. Popkin.  Exacerbation of recurrent depression as a result of treatment with varenicline. , 2008, The American journal of psychiatry.

[70]  M. Keshavan,et al.  Schizophrenia, “just the facts”: What we know in 2008 Part 3: Neurobiology , 2008, Schizophrenia Research.

[71]  Joseph A. Gogos,et al.  Palmitoylation-dependent neurodevelopmental deficits in a mouse model of the 22q11 microdeletion , 2008, Nature Neuroscience.

[72]  S Marenco,et al.  Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk , 2008, Molecular Psychiatry.

[73]  T. Franke,et al.  PI3K/Akt: getting it right matters , 2008, Oncogene.

[74]  John P A Ioannidis,et al.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database , 2008, Nature Genetics.

[75]  Jennifer E. Chubb,et al.  The DISC locus in psychiatric illness , 2008, Molecular Psychiatry.

[76]  G. Collingridge,et al.  The role of GSK‐3 in synaptic plasticity , 2008, British journal of pharmacology.

[77]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[78]  Yue-Cune Chang,et al.  Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study , 2008, Biological Psychiatry.

[79]  H. Moore,et al.  Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components , 2008, The Journal of Neuroscience.

[80]  P. Aisen,et al.  A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[81]  D. Javitt.  Glycine Transport Inhibitors and the Treatment of Schizophrenia , 2008, Biological Psychiatry.

[82]  B. Dean,et al.  Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? , 2008, Journal of neurochemistry.

[83]  Craig Mallinckrodt,et al.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. , 2008, The American journal of psychiatry.

[84]  G. Winterer,et al.  The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia , 2008, Pharmacopsychiatry.

[85]  Holly Moore,et al.  A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition , 2008, Proceedings of the National Academy of Sciences.

[86]  A M McIntosh,et al.  The effects of a neuregulin 1 variant on white matter density and integrity , 2008, Molecular Psychiatry.

[87]  A. Fisahn,et al.  Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. , 2009, Cerebral cortex.

[88]  E. Kandel,et al.  Modeling cognitive endophenotypes of schizophrenia in mice , 2009, Trends in Neurosciences.

[89]  A. Lajtha,et al.  Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder , 2009, Schizophrenia Research.

[90]  Li-Huei Tsai,et al.  Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin Signaling , 2009, Cell.

[91]  R. Vakkalanka,et al.  DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms , 2009, Proceedings of the National Academy of Sciences.

[92]  P. Chan,et al.  Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival , 2009, Journal of neurochemistry.

[93]  Akira Sawa,et al.  Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1–ErbB4 and DISC1 , 2009, Trends in Neurosciences.

[94]  Takeshi Sakurai,et al.  Linking White and Grey Matter in Schizophrenia: Oligodendrocyte and Neuron Pathology in the Prefrontal Cortex , 2009, Front. Neuroanat..

[95]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[96]  W. Danysz,et al.  Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. , 2009, European journal of pharmacology.

[97]  Craig W Lindsley,et al.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. , 2009, Trends in pharmacological sciences.

[98]  C. Wass,et al.  Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide , 2009, Neuropsychopharmacology.

[99]  C. Ross,et al.  Animal models of gene–environment interactions in schizophrenia , 2009, Behavioural Brain Research.

[100]  M. Quirk,et al.  Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. , 2009, Biochemical pharmacology.

[101]  J. Waddington,et al.  Mutant models for genes associated with schizophrenia. , 2009, Biochemical Society transactions.

[102]  J. Sebat,et al.  Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. , 2009, Trends in genetics : TIG.

[103]  P. Jia,et al.  SZGR: a comprehensive schizophrenia gene resource , 2009, Molecular Psychiatry.

[104]  J. Gordon,et al.  Impaired hippocampal–prefrontal synchrony in a genetic mouse model of schizophrenia , 2010, Nature.

[105]  Tony J. Simon,et al.  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia , 2010, Nature Reviews Neuroscience.